[go: up one dir, main page]

EP1047425A4 - Integrin receptor antagonists - Google Patents

Integrin receptor antagonists

Info

Publication number
EP1047425A4
EP1047425A4 EP98962096A EP98962096A EP1047425A4 EP 1047425 A4 EP1047425 A4 EP 1047425A4 EP 98962096 A EP98962096 A EP 98962096A EP 98962096 A EP98962096 A EP 98962096A EP 1047425 A4 EP1047425 A4 EP 1047425A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
integrin receptor
integrin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98962096A
Other languages
German (de)
French (fr)
Other versions
EP1047425A1 (en
Inventor
Mark E Duggan
Robert S Meissner
James J Perkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810182.7A external-priority patent/GB9810182D0/en
Priority claimed from GBGB9811283.2A external-priority patent/GB9811283D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1047425A1 publication Critical patent/EP1047425A1/en
Publication of EP1047425A4 publication Critical patent/EP1047425A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
EP98962096A 1997-12-17 1998-12-14 Integrin receptor antagonists Withdrawn EP1047425A4 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6991097P 1997-12-17 1997-12-17
US69910P 1997-12-17
US8325198P 1998-04-27 1998-04-27
US83251P 1998-04-27
GB9810182 1998-05-13
GBGB9810182.7A GB9810182D0 (en) 1998-05-13 1998-05-13 Vitronectin receptor antagonists
GB9811283 1998-05-26
GBGB9811283.2A GB9811283D0 (en) 1998-05-26 1998-05-26 Vironectin receptor antagonists
US9258898P 1998-07-13 1998-07-13
US92588P 1998-07-13
PCT/US1998/026539 WO1999030709A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (2)

Publication Number Publication Date
EP1047425A1 EP1047425A1 (en) 2000-11-02
EP1047425A4 true EP1047425A4 (en) 2009-04-22

Family

ID=27517457

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98962096A Withdrawn EP1047425A4 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Country Status (5)

Country Link
EP (1) EP1047425A4 (en)
JP (1) JP2002508323A (en)
AU (1) AU736026B2 (en)
CA (1) CA2315370A1 (en)
WO (1) WO1999030709A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
CA2338878A1 (en) * 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CN1589145A (en) 1999-06-02 2005-03-02 麦克公司 Alpha v integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
CA2386030A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
US6849639B2 (en) * 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP4787447B2 (en) * 2000-01-20 2011-10-05 メルク・シャープ・エンド・ドーム・コーポレイション αv integrin receptor antagonist
WO2001053302A1 (en) * 2000-01-24 2001-07-26 Sagami Chemical Research Center 5H-QUINOXALINO[2,3-b]NAPHTHO[2,1][1,4]OXAZIN-5-ONE AND INTERMEDIATE FOR THE PREPARATION THEREOF
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
EP1289983A2 (en) * 2000-06-15 2003-03-12 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
IT1317049B1 (en) 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti USEFUL COMPOUNDS FOR THE PREPARATION OF MEDICATIONS FOR PHOSPHODIESTERASE INHIBITING ACTIVITIES IV.
JP2004502762A (en) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド Squaric acid derivatives as integrin antagonists containing bicyclic heteroaromatic rings
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
AU9088401A (en) * 2000-09-13 2002-03-26 Merck & Co Inc Alpha v integrin receptor antagonists
CA2421652A1 (en) 2000-09-14 2002-03-21 Merck And Co., Inc. Alpha v integrin receptor antagonists
ES2366775T3 (en) 2001-04-24 2011-10-25 Merck Patent Gmbh POLYTHERAPY USING ANTIANGIOGEN AGENTS AND TNF (alpha).
US20030171368A1 (en) * 2002-02-06 2003-09-11 Werner Seitz Pyrimidinonesulfamoylureas`
AU2003297408A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
AU2004242928B2 (en) 2003-05-30 2011-03-10 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
EA011010B1 (en) 2004-02-27 2008-12-30 Эмджен, Инк. Compounds modulating of gpr40 receptor, pharmaceutical composition, method for treating diseases responsive to the modulation of gpr40 receptor (embodiments), method for modulating gpr40 function (embodiments) and method for modulating circulating insulin concentration
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20070299114A1 (en) * 2004-10-05 2007-12-27 Shionogi & Co., Ltd. Biaryl Derivatives
ES2521679T3 (en) 2006-01-18 2014-11-13 Merck Patent Gmbh Specific therapy using integrin ligands for cancer treatment
AU2008207095B2 (en) 2007-01-18 2013-08-29 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
KR20120104491A (en) 2009-05-25 2012-09-21 메르크 파텐트 게엠베하 Continuous administration of cilengitide in cancer treatments
SG189420A1 (en) 2010-11-11 2013-05-31 Sanofi Sa Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
CN108690022B (en) 2013-02-07 2021-08-17 赛弗卢尔生命科学公司 Fluorinated integrin antagonists
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
HUE057203T2 (en) 2013-09-24 2022-04-28 Fujifilm Corp Novel nitrogen-containing compound or salt thereof, or metal complex thereof
JP6649902B2 (en) 2014-05-30 2020-02-19 ファイザー・インク Carbonitrile derivatives as selective androgen receptor modulators
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
BR112017017888A2 (en) 2015-02-19 2018-04-10 Scifluor Life Sciences Inc fluorinated derivatives of tetrahydronaphthyridinyl nonanoic acid derivatives and uses of these
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
AU2017359030A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
HUE059708T2 (en) * 2016-11-08 2022-12-28 Bristol Myers Squibb Co 3-substituted propionic acids as alpha-V-integrin inhibitors
EA201991121A1 (en) 2016-11-08 2019-11-29 ASOLAMIDES AND ASOLAMINES AS αV INTEGRIN INHIBITORS
CN110214137A (en) 2016-11-08 2019-09-06 百时美施贵宝公司 As αvThe indazole derivative of integrin antagonists
WO2018089355A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
RU2022108080A (en) 2017-02-28 2022-04-07 Морфик Терапьютик, Инк. INTEGRIN AVB6 INHIBITORS
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2019094319A1 (en) 2017-11-07 2019-05-16 Bristol-Myers Squibb Company Pyrrolopyrazine derivatives as alpha v integrin inhibitors
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
JP7668621B2 (en) * 2019-03-29 2025-04-25 健裕生技股▲分▼有限公司 Compounds for promoting myocardial regeneration, methods for preparing same, pharmaceutical compositions and uses thereof
JP6768868B2 (en) * 2019-03-29 2020-10-14 健裕生技股▲分▼有限公司 Compounds for promoting myocardial regeneration, methods for preparing them, and their use
US11124472B2 (en) 2019-04-08 2021-09-21 Genhealth Pharma Co., Ltd. Myocardial regeneration promoting compounds, preparation method thereof, and pharmaceutical composition
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1025439A (en) * 1963-10-09 1966-04-06 Abbott Lab Nitrofuryl substituted oxadiazoles
DE1620057A1 (en) * 1965-12-13 1970-03-19 Miles Lab Process for the preparation of omega (5-substituted-2-tetrazolyl) alkanoic acids
DE1946638A1 (en) * 1968-09-13 1970-09-03 Ici Ltd Heterocyclic compounds
WO1995006038A1 (en) * 1993-08-24 1995-03-02 G.D. Searle & Co. Platelet aggregation inhibitors
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5295661A (en) * 1976-02-04 1977-08-11 Yoshitomi Pharmaceut Ind Ltd 5-alkoxy-4-oxazolealkanoic acid derivatives
US4480106A (en) * 1981-10-28 1984-10-30 Ciba-Geigy Corporation Process for the preparation of asymmetrically substituted maleic anhydrides, and asymmetrically substituted maleic anhydrides
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
JPH09165370A (en) * 1995-10-13 1997-06-24 Fuji Yakuhin Kogyo Kk Lactam derivative and its salt
KR19990076876A (en) * 1995-12-29 1999-10-25 스티븐 베네티아너 Bitronectin receptor antagonist
HUP9900754A3 (en) * 1995-12-29 1999-11-29 Smithkline Beecham Corp Vitronectin receptor antagonists
BR9612381A (en) * 1995-12-29 1999-07-13 Smithkline Beecham Corp Vitronectin receptor antagonists
DK0796855T3 (en) * 1996-03-20 2002-05-27 Hoechst Ag Inhibitors of bone resorption and vitronectin receptor antagonists
JP4289688B2 (en) * 1996-04-03 2009-07-01 武田薬品工業株式会社 Oxazole derivatives, production methods and agents thereof
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
WO1998027108A2 (en) * 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
JP3589633B2 (en) * 1997-12-17 2004-11-17 メルク エンド カムパニー インコーポレーテッド Integrin receptor antagonist

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1025439A (en) * 1963-10-09 1966-04-06 Abbott Lab Nitrofuryl substituted oxadiazoles
DE1620057A1 (en) * 1965-12-13 1970-03-19 Miles Lab Process for the preparation of omega (5-substituted-2-tetrazolyl) alkanoic acids
DE1946638A1 (en) * 1968-09-13 1970-09-03 Ici Ltd Heterocyclic compounds
WO1995006038A1 (en) * 1993-08-24 1995-03-02 G.D. Searle & Co. Platelet aggregation inhibitors
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9930709A1 *

Also Published As

Publication number Publication date
WO1999030709A1 (en) 1999-06-24
EP1047425A1 (en) 2000-11-02
AU1725799A (en) 1999-07-05
CA2315370A1 (en) 1999-06-24
AU736026B2 (en) 2001-07-26
JP2002508323A (en) 2002-03-19

Similar Documents

Publication Publication Date Title
EP1047425A4 (en) Integrin receptor antagonists
EP1007051A4 (en) Integrin receptor antagonists
EP1100506A4 (en) Integrin receptor antagonists
EP1105389A4 (en) Integrin receptor antagonists
EP1007026A4 (en) Integrin antagonists
EP0934305A4 (en) Integrin antagonists
ZA9896B (en) Vitronectin receptor antagonists
EP0880511A4 (en) Integrin receptor antagonists
EP0946164A4 (en) Integrin antagonists
EP1194151A4 (en) Integrin receptor antagonists
EP1229910A4 (en) Integrin receptor antagonists
IL135797A0 (en) Thrombin receptor antagonists
IL135028A0 (en) Vitronectin receptor antagonists
PL342881A1 (en) Vitronectin receptor antagonists
EP1027337A4 (en) Integrin receptor antagonists
IL148043A0 (en) Novel integrin receptor antagonists
IL146146A0 (en) Integrin receptor antagonists
PL346157A1 (en) Vitronectin receptor antagonists
ZA9811500B (en) Integrin receptor antagonists
ZA986930B (en) Integrin receptor antagonists
IL119820A0 (en) Integrin receptor antagonists
GB9603373D0 (en) Integrin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
ZA9610690B (en) Integrin receptor antagonists.
GB9811283D0 (en) Vironectin receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000717;LT PAYMENT 20000717;LV PAYMENT 20000717;MK PAYMENT 20000717;RO PAYMENT 20000717;SI PAYMENT 20000717

A4 Supplementary search report drawn up and despatched

Effective date: 20090325

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 519/00 20060101ALI20090319BHEP

Ipc: C07D 401/14 20060101ALI20090319BHEP

Ipc: C07D 401/06 20060101ALI20090319BHEP

Ipc: C07D 471/04 20060101ALI20090319BHEP

Ipc: C07D 413/06 20060101ALI20090319BHEP

Ipc: C07D 207/26 20060101ALI20090319BHEP

Ipc: A61K 31/40 20060101ALI20090319BHEP

Ipc: A61K 31/435 20060101AFI19990706BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

17Q First examination report despatched

Effective date: 20090721

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701